ELVN Q1 2021 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$25,000

Operating Income

-$10M

Net Income

-$10M

EPS (Diluted)

$-2.33

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$82M

Total Liabilities

$6M

Stockholders' Equity

$76M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$25,000	$0	—
Operating Income	-$10M	-$7M	-39.8%
Net Income	-$10M	-$7M	-42.2%